# Alnylam Pharmaceuticals account plan

> Alnylam Pharmaceuticals is an RNAi biopharmaceutical company with six approved medicines, led by AMVUTTRA; about 2,500 employees.

## At a glance

Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company built on RNA interference (RNAi), headquartered in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland. It has six approved first-in-class RNAi medicines: it sells AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO itself, mainly in the U.S. and Europe, and earns royalties on Leqvio (Novartis) and Qfitlia (Sanofi). FY2025 total revenues were $3,713,937 thousand (+65%), and the company reached profitability for the first time, with net income of $313,747 thousand. It had about 2,500 full-time employees at 31 December 2025, about 1,945 of them in the U.S.

## Business units

- **TTR franchise (AMVUTTRA, ONPATTRO)** (about 67% of FY2025 total revenues ($2,486,625 thousand)): Medicines for transthyretin (ATTR) amyloidosis. AMVUTTRA sold $2,313,836 thousand in FY2025 (+138%) after its March 2025 FDA approval in ATTR-CM, while ONPATTRO declined as patients moved to AMVUTTRA. Q3 2026 TTR revenues were $1,150 million (+59%).
- **Rare franchise (GIVLAARI, OXLUMO)** (about 13% of FY2025 total revenues ($499,924 thousand)): GIVLAARI treats acute hepatic porphyria and OXLUMO primary hyperoxaluria type 1; both are held globally by Alnylam. Q3 2026 Rare revenues were $142 million (+12%).
- **Collaborations** (about 15% of FY2025 total revenues ($553,366 thousand)): Revenue from partners Roche (zilebesiran, hypertension), Regeneron (cemdisiran and CNS programs) and others. FY2025 included the $300.0 million Roche ZENITH milestone, so Q3 2026 collaboration revenue fell 80% to $71,476 thousand.
- **Royalties** (about 5% of FY2025 total revenues ($174,022 thousand)): Mainly royalties on Novartis's Leqvio for LDL cholesterol lowering, plus Qfitlia sold by Sanofi. Q3 2026 royalty revenue more than doubled to $94,664 thousand.

## Strategic priorities

- **Alnylam 2030 revenue and margin targets**: The Alnylam 2030 strategy, launched early 2026, targets a 25%+ total revenue CAGR through year-end 2030 and ~30% non-GAAP operating margin, reinvesting ~30% of revenues in non-GAAP R&D.
- **TTR market leadership**: Alnylam aims to lead the market in TTR revenue by 2030 and launch nucresiran in ATTR polyneuropathy by 2028 and cardiomyopathy by 2030; the CEO frames growth around capturing a third of U.S. category TRx in a treated ATTR-CM population of about 75,000 by 2030.
- **Expanding the AMVUTTRA prescriber base**: The field force was expanded by about 25% to reach the two-thirds of targeted physicians who have not yet prescribed AMVUTTRA; about 80% of prevalent ATTR-CM patients remain untreated.
- **New medicines beyond TTR**: The strategy targets 2+ new blockbuster-potential medicines beyond TTR, 10 tissue types and >40 clinical programs; brezosiran for Huntington's disease heads to a pivotal study in 2027.
- **Lower production costs**: The Norton, Massachusetts plant is being expanded for the siRELIS enzymatic ligation platform to increase capacity and reduce production costs; nucresiran carries no Sanofi royalties.

## Latest results

In Q3 2026 total revenues were $1,458,086 thousand (+17%) and net product revenues $1,291,946 thousand (+52%), with AMVUTTRA at $1,130,363 thousand (+65%). Total revenues were held back by comparison with the $300.0 million Roche milestone of Q3 2025, and income from operations fell 6% to $345,798 thousand as cost of goods sold reached 28.0% of net product revenues on higher Sanofi royalties. Net income of $2,167,335 thousand included a $1,871,525 thousand tax benefit. Nine-month revenues were $3,916,209 thousand (+50%). 2026 guidance was reiterated at net product revenues of $4,700 million - $5,100 million, with TTR sales expected at the low end of the $4.2 billion-$4.5 billion range; 2027 guidance moves to mid-February.

## Investments and deals

- **Norton manufacturing expansion**: Expansion of the 200,000 sq ft Norton, Massachusetts drug-substance plant, announced in December 2025, adds the siRELIS enzymatic ligation platform. FY2025 capital expenditures were $58.7 million, expected to increase in 2026.
- **Phase 3 trials**: R&D spend was $1,319,775 thousand in FY2025, driven by the ZENITH, TRITON-CM and TRITON-PN Phase 3 trials; TRITON-CM enrollment was expanded twice in 2026 to about 2,250 patients.
- **AI collaboration with Inceptive Nucleics**: A June 2026 collaboration integrates Inceptive's generative AI models with Alnylam's pipeline, with a $15.0 million purchase of Inceptive preferred stock.
- **Field force expansion**: The sales field force was expanded by about 25% to raise physician engagement for AMVUTTRA.
- **Convertible refinancing and credit facility**: In September 2025 Alnylam issued $661.3 million of 0.00% convertible notes due 2028 and entered a $500.0 million revolving credit facility, undrawn.

## Challenges and risks

- **Slower AMVUTTRA demand growth**: The CEO said Alnylam is not yet satisfied with underlying demand growth; the expanded sales force is raising engagement but not yet patient starts, and no acceleration is expected in Q4 2026.
- **340B and payer restrictions**: A CMS 340B reimbursement change from ASP +6% to ASP -28% takes effect January 1, 2027, and UnitedHealth and Aetna added step edits.
- **Rising royalty costs**: Cost of goods sold rose to 28.0% of net product revenues in Q3 2026 from 23.2% as the blended Sanofi royalty rate on AMVUTTRA rose, with tiers up to 30%.
- **Dependence on AMVUTTRA and competition**: The 10-K names dependence on AMVUTTRA as a key risk, with competition from tafamidis, acoramidis, eplontersen and gene editing.
- **First-line patient mix**: 2026 TTR guidance was cut to $4.2 billion-$4.5 billion as the patient mix moved toward the market's 80% first line / 20% second line.

## What leadership says

> "we're not yet satisfied with the underlying demand growth we have observed" — Yvonne Greenstreet, Chief Executive Officer, Q3 2026 earnings call, October 29, 2026

> "laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients" — Yvonne Greenstreet, Chief Executive Officer, Third quarter 2026 financial results press release, October 29, 2026

> "in cardiology, behavioral change takes some time" — Yvonne Greenstreet, Chief Executive Officer, Jefferies Global Healthcare Conference fireside chat, November 18, 2026

> "crossed a billion of revenue in just one quarter" — Yvonne Greenstreet, Chief Executive Officer, Morgan Stanley Global Healthcare Conference fireside chat, September 14, 2026, on AMVUTTRA in Q2 2026


## Where a supplier can help

- **Commercial targeting and field-force effectiveness**: Tied to the prescriber-base priority and the slower demand growth: physician targeting data, CRM analytics and omnichannel engagement help the expanded field force turn engagement into patient starts.
- **Market access and 340B contracting**: Tied to the 340B reimbursement change and payer step edits: contracting, reimbursement and patient-access services support the work with about 200 340B institutions.
- **Manufacturing scale-up at Norton**: Tied to the Norton expansion and lower production costs: process equipment, engineering and quality services fit the siRELIS build-out.
- **Clinical trial delivery**: Tied to the three Phase 3 trials and the enlarged TRITON-CM study: CRO capacity, patient recruitment and trial data services address heavier clinical spend.
- **AI and data for discovery**: Tied to the Inceptive Nucleics collaboration and the >40 clinical programs target: AI, data infrastructure and genetics partners support pipeline expansion.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm)

Annual report · 2026-02-12

- Alnylam is a global commercial-stage biopharmaceutical company built on RNA interference (RNAi): six approved first-in-class RNAi medicines (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, plus Leqvio sold by Novartis and Qfitlia sold by Sanofi) and more than 20 clinical programs.
- FY2025 total revenues were $3,713,937 thousand (+65%), and the company "achieved profitability for the first time in 2025": income from operations $501,578 thousand and net income $313,747 thousand.
- AMVUTTRA is the growth engine: $2,313,836 thousand of net product revenues (+138%), driven by the March 2025 FDA approval in ATTR amyloidosis with cardiomyopathy (ATTR-CM); U.S. AMVUTTRA sales rose 175%.
- The Alnylam 2030 strategy, launched early 2026, targets TTR market leadership, 2+ new blockbuster-potential medicines beyond TTR, 10 tissue types and >40 clinical programs, 25%+ total revenue CAGR through year-end 2030 and ~30% non-GAAP operating margin, with ~30% of revenues reinvested in non-GAAP R&D.
- Next-generation TTR silencer nucresiran is in two Phase 3 trials (TRITON-PN, TRITON-CM); zilebesiran (hypertension, with Roche) entered the Phase 3 ZENITH outcomes trial, triggering a $300 million Roche milestone.
- R&D spend was $1,319,775 thousand and SG&A $1,210,713 thousand; cost of goods sold rose to 22.7% of net product revenues because of tiered royalties (up to 30%) owed to Sanofi on AMVUTTRA sales.
- About 2,500 full-time employees (about 1,945 in the U.S.), ~270 added in 2025; Norton, Massachusetts manufacturing site being expanded for the siRELIS enzymatic ligation platform; most drug substance comes from CMOs (Agilent is sole API source for AMVUTTRA, ONPATTRO and GIVLAARI).
- Cash, cash equivalents and marketable securities were $2.91 billion at 31 December 2025; key risks are dependence on AMVUTTRA, competition (tafamidis, acoramidis, eplontersen, gene editing), pricing/reimbursement and convertible debt.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm)

Interim report · 2026-10-29

- Q3 2026 total revenues $1,458,086 thousand (+17%); nine-month revenues $3,916,209 thousand (+50%).
- Q3 net product revenues $1,291,946 thousand (+52%), of which AMVUTTRA $1,130,363 thousand (+65%); U.S. AMVUTTRA $908,596 thousand (+71%).
- Collaboration revenue fell 80% to $71,476 thousand against the $300.0 million Roche ZENITH milestone of Q3 2025; royalty revenue more than doubled to $94,664 thousand on Leqvio.
- Cost of goods sold reached 28.0% of net product revenues (23.2% a year earlier) as the blended royalty rate to Sanofi on AMVUTTRA rose.
- Income from operations $345,798 thousand (-6%); net income $2,167,335 thousand including a $1,871,525 thousand tax benefit from releasing U.S. valuation allowances.
- TRITON-CM (nucresiran) target enrollment expanded twice in 2026, from 1,250 to about 1,750 and then to about 2,250 patients; ATTR-CM launch still expected by 2030.
- Brezosiran (Huntington's disease) showed positive initial Phase 1b results; a placebo-controlled pivotal study is planned for 2027. Regeneron's cemdisiran NDA has a November 2026 target action date.
- New June 2026 AI collaboration with Inceptive Nucleics ($15.0 million preferred-stock investment); Regeneron's exclusive research term expired in May 2026.

### [Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results (press release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/alny2026q3earningsrelease.htm)

Interim report · 2026-10-29

- Q3 2026 global net product revenues of $1,292 million (+52%), of which total TTR $1,150 million (+59%) and total Rare $142 million (+12%).
- U.S. TTR revenues rose $99 million versus Q2 2026: $81 million from demand, a $17 million inventory benefit and about $10 million of favorable gross-to-net adjustments.
- Non-GAAP income from operations $424,916 thousand (-11%); non-GAAP R&D $375,677 thousand (+21%) and non-GAAP SG&A $295,743 thousand (+13%).
- Cash, cash equivalents and marketable securities $3.6 billion at 30 September 2026 (vs $2.9 billion at year-end 2025).
- 2026 guidance reiterated: total TTR $4,200 million - $4,500 million, total Rare $500 million - $600 million, net product revenues $4,700 million - $5,100 million, collaboration and royalty revenues $575 million - $625 million, non-GAAP R&D and SG&A $2,700 million - $2,800 million.
- TRITON-CM expanded to about 2,250 patients; positive Phase 1 data for brezosiran in Huntington's disease with mean CSF mHTT reduction of 60-64%; pivotal study planned for 2027.
- CEO Yvonne Greenstreet: "laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients".

### [Alnylam Q3 2026 earnings call transcript](https://stockanalysis.com/stocks/alny/transcripts/719861-q3-2026/)

Executive talk · Yvonne Greenstreet, Chief Executive Officer · 2026-10-29

- CEO Yvonne Greenstreet: "we're not yet satisfied with the underlying demand growth we have observed"; the expanded sales force is raising physician engagement but not yet patient starts, and no acceleration is expected in Q4 2026.
- About a third of active ATTR prescribers have used AMVUTTRA; more than 2,000 new unique prescribers since the CM launch; AMVUTTRA holds about 24% of total TTR prescriptions (TRx) and north of 30% of new-to-brand prescriptions.
- About 80% of prevalent ATTR-CM patients remain untreated; total ATTR-CM prescriptions grew nearly 40% year-over-year.
- CFO Jeff Poulton: 2026 TTR sales expected at the low end of the $4.2 billion-$4.5 billion range; no material top-line contribution assumed from the field expansion in 2026.
- Headwinds: a proposed CMS 340B reimbursement rule effective January 1st, 2027 and a more restrictive first-line policy at UnitedHealth (Medicare Advantage) from October 1st; 2027 guidance moved to mid-February.
- R&D head Pushkal Garg: TRITON-CM enlarged by 500 patients to 2,250 to protect against falling event rates; launch still around 2030.
- Brezosiran (Huntington's) heading to a pivotal study in 2027; ALN-6400 HHT and ALN-2232 obesity data due in February.
- Greenstreet still frames the 25% revenue CAGR around capturing a third of U.S. category TRx in a treated ATTR-CM population of about 75,000 by 2030.

### [Jefferies Global Healthcare Conference (London) fireside chat transcript](https://stockanalysis.com/stocks/alny/transcripts/795540-jefferies-global-healthcare-conference/)

Executive talk · Yvonne Greenstreet, Chief Executive Officer · 2026-11-18

- CEO Yvonne Greenstreet: the field force has been expanded "by about 25%" to reach the two-thirds of targeted physicians who have not yet prescribed AMVUTTRA; Alnylam is now "up to 2,000 prescribers".
- The focus is execution: more frequent, more intense physician engagement, more precise targeting and tailored messages, because "in cardiology, behavioral change takes some time".
- The departing Chief Commercial Officer will be replaced by someone able to drive AMVUTTRA's next growth phase and "multiple launches beyond AMVUTTRA"; a search is ongoing.
- CFO Jeff Poulton: about 99% of U.S. lives are covered and about 75% have first-line access; original Medicare is about 50% of current patients, Medicare Advantage about 35%. UnitedHealth (about 10% of lives) and Aetna (about 5%) added step edits.
- 340B: reimbursement changes from ASP +6% to ASP -28% on January 1; AMVUTTRA lists at about $475,000 a year. Alnylam will contract with about 200 340B institutions, with its approach in place by mid-December, and guide 2027 in February.
- CMO Pushkal Garg: TRITON-CM enlarged twice by 500 patients to 2,250 to protect against falling event rates; nucresiran silences about 95% of TTR twice a year; results and launch around 2030.

### [Morgan Stanley 24th Annual Global Healthcare Conference fireside chat transcript](https://stockanalysis.com/stocks/alny/transcripts/744074-morgan-stanley-24th-annual-global-healthcare-conference/)

Executive talk · Yvonne Greenstreet, Chief Executive Officer · 2026-09-14

- CEO Yvonne Greenstreet: AMVUTTRA "crossed a billion of revenue in just one quarter" in Q2 2026, following the March 2025 ATTR-CM approval.
- Launch drivers: HELIOS-B data, quarterly subcutaneous dosing, access with most patients at $0 out of pocket, and over 50% market share among physicians who have used AMVUTTRA.
- The 2026 TTR guidance was cut to $4.2 billion-$4.5 billion ($200 million lower at the midpoint) as the patient mix moved from balanced first/second line towards the market's 80% first line / 20% second line.
- Market of roughly 200,000 ATTR-CM patients in the U.S. and 500,000 worldwide, 80% yet to be diagnosed and treated.
- Generic tafamidis now expected in 2031 rather than 2028, which she calls "a pretty good thing for AMVUTTRA"; TRITON-PN data in 2028 and TRITON-CM around 2030.
- Pipeline catalysts: Huntington's Phase 1 data in October, ALN-6400 in bleeding disorders, a first adipose-targeting obesity program, zilebesiran outcomes study; an AI deal with Inceptive Nucleics.
- SVP John Kennedy expects only "a modest and gradual reduction in net price" and points to an alternate-site network if the 340B rule passes.

## Questions about Alnylam Pharmaceuticals

### What does Alnylam Pharmaceuticals do?

Alnylam develops and sells RNA interference (RNAi) medicines that silence the genes behind disease. It has six approved RNAi medicines, led by AMVUTTRA for ATTR amyloidosis.

### What is Alnylam's revenue?

FY2025 total revenues were $3,713,937 thousand, up 65%, with net income of $313,747 thousand. Q3 2026 total revenues were $1,458,086 thousand (+17%).

### How many employees does Alnylam have?

About 2,500 full-time employees at 31 December 2025, about 1,945 in the U.S., after about 270 were added in 2025.

### Who leads Alnylam?

Yvonne Greenstreet is Chief Executive Officer; Jeff Poulton is CFO and Pushkal Garg leads R&D as CMO.

### What is Alnylam's strategy?

The Alnylam 2030 strategy targets TTR market leadership, 2+ new blockbuster-potential medicines beyond TTR, a 25%+ revenue CAGR through 2030 and ~30% non-GAAP operating margin.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
